Open AccessCardiovascular Safety of Oral Antidiabetic Agents: The Insulin Secretagogues
Author(s) -
Michael T. Caulfield,
Kevin D. O’Brien
Publication year - 2002
Publication title -
clinical diabetes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.931
H-Index - 37
eISSN - 1945-4953
pISSN - 0891-8929
DOI - 10.2337/diaclin.20.2.81
Subject(s) - medicine , sulfonylurea , insulin , cardiotoxicity , diabetes mellitus , type 2 diabetes , pharmacology , endocrinology , toxicity
In Brief This article reviews and dispels concerns about the potential cardiotoxicity of insulin and oral diabetes drugs, specifically the insulin secretagogues, in patients with type 2 diabetes. The authors focus on insulin and the sulfonylurea drugs but also briefly discuss meglitinide analogs.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom